GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Core Viewpoint - GRI Bio, Inc. is advancing its innovative pipeline of NKT cell modulators aimed at treating inflammatory, fibrotic, and autoimmune diseases, with recent achievements in expanding its global patent estate [1][2]. Patent Developments - The company has been granted two global patents, enhancing its intellectual property portfolio and supporting its innovative pipeline of over 500 proprietary compounds [2][5]. - The patents include coverage for GRI-0803, a novel activator of human type 2 diverse NKT cells for treating autoimmune disorders, and methods for modulating NKT cells in inflammatory conditions [5]. Clinical Development - GRI Bio is advancing its lead program, GRI-0621, in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF), with interim data expected in Q2 2025 and topline results in Q3 2025 [2][3]. - The company’s therapies target NKT cells to interrupt disease progression and restore immune system balance, addressing significant unmet medical needs [3]. Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on transforming the treatment landscape for inflammatory, fibrotic, and autoimmune diseases through its unique approach to NKT cell modulation [3].